PMID- 18528474
OWN - NLM
STAT- MEDLINE
DCOM- 20090402
LR  - 20240412
IS  - 0065-7778 (Print)
IS  - 0065-7778 (Linking)
VI  - 117
DP  - 2006
TI  - Desensitization therapy with intravenous gammaglobulin (IVIG): applications in 
      solid organ transplantation.
PG  - 199-211; discussion 211
AB  - Intravenous immunoglobulin products (IVIG) are derived from pooled human plasma 
      and have been used for the treatment of primary immunodeficiency disorders for 
      more than 24 years. Shortly after their introduction, IVIG products were found to 
      be effective in the treatment of autoimmune and inflammatory disorders. Over the 
      past 2 decades, the list of diseases where IVIG has a demonstrable beneficial 
      effect has grown rapidly. These include inflammatory diseases such as Kawasaki 
      disease, Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and 
      demyelinating polyneuropathy. Recently, we have described a beneficial effect on 
      the reduction of anti-HLA antibodies with subsequent improvement in rates of 
      transplantation for highly human leukocyte antigen (HLA) sensitized patients as 
      well as a potent anti-inflammatory effect that is beneficial in the treatment of 
      antibody-mediated rejection (AMR). These advancements have enabled 
      transplantation of patients previously considered untransplantable and in concert 
      with new diagnostic techniques has resulted in new approaches to management of 
      AMR.
FAU - Jordan, Stanley C
AU  - Jordan SC
AD  - Comprehensive Transplant Center, Cedars-Sinai Medical Center, David Geffen School 
      of Medicine at UCLA, Los Angeles, CA 90048, USA.
FAU - Vo, Ashley
AU  - Vo A
FAU - Tyan, Dolly
AU  - Tyan D
FAU - Toyota, Mieko
AU  - Toyota M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Trans Am Clin Climatol Assoc
JT  - Transactions of the American Clinical and Climatological Association
JID - 7507559
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Antibodies, Viral/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cytomegalovirus/immunology
MH  - Desensitization, Immunologic/*methods
MH  - Graft Rejection/immunology/therapy
MH  - HLA Antigens
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Kidney Transplantation/immunology
MH  - Plasmapheresis
MH  - *Transplantation Immunology
PMC - PMC1500934
EDAT- 2008/06/06 09:00
MHDA- 2009/04/03 09:00
PMCR- 2006/01/01
CRDT- 2008/06/06 09:00
PHST- 2008/06/06 09:00 [pubmed]
PHST- 2009/04/03 09:00 [medline]
PHST- 2008/06/06 09:00 [entrez]
PHST- 2006/01/01 00:00 [pmc-release]
PST - ppublish
SO  - Trans Am Clin Climatol Assoc. 2006;117:199-211; discussion 211.